#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

ANCA-associated vasculitis from a clinical perspective


Authors: Zdenka Hrušková 1;  Vladimír Tesař 1
Authors place of work: Klinika nefrologie VFN v Praze a 1. LF UK, Praha 1
Published in the journal: Čes.-slov. Patol., 60, 2024, No. 3, p. 150-154
Category: Reviews Article

Summary

ANCA-associated vasculitides (AAV) are small-vessel necrotizing vasculitides, with no or few immune deposits. They are usually associated with the presence of ANCA antibodies (AntiNeutrophil Cytoplasmic Antibody), targeted either against proteinase 3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA). ANCA-associated vasculitides include granulomatosis with polyangiitis (formerly Wegener‘s), microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome). The most commonly afflicted organs involve the lungs and the respiratory tract, ENT area, and the kidneys. Renal involvement typically manifests as pauci-immune necrotizing crescentic rapidly progressive glomerulonpehritis. Pulmo-renal syndrome with lung haemorrhage and deteriorating kidney function may be acutely life-threatening. Diagnostic methods include ANCA measurement, imaging methods and biopsy. Early recognition of the diagnosis and an early start of adequate treatment are necessary for a good outcome. The current treatment typically consists of corticosteroids and either cyclophoshapmide or rituximab (a monoclonal antibody directed against CD20 antigen). The addition of plasma exchange may be considered in severe cases. Rituximab is preferred for the treatment of all relapsing forms of this vasculitis.

Keywords:

Biopsy – vasculitis – granulomatosis with polyangiitis – ANCA – treatment


Zdroje
  1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 Revised international Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis & Rheum 2013; 65: 1-11.
  2. Hrušková Z, Tesař V. Vaskulitidy. In: Widimský P, Rychlík I, et al. Vnitřní lékařství I. díl. 1. vydání. Maxdorf, Praha, 2023.
  3. Hrušková Z, Tesař V. Doporučení pro léčbu ANCA asociované vaskulitidy. In: Ryšavá R, Viklický O, et al. Vybrané doporučené postupy v nefrologii. 1. vydání. Maxdorf, Praha, 2022.
  4. Bossuyt X, Cohen Tervaert JW, et al. Position paper: Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 2017; 13: 683-692.
  5. Almaani S, Fussner LA, Brodsky S, et al. ANCA-Associated Vasculitis: An Update. J Clin Med 2021; 10: 1446.
  6. Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367: 214-223.
  7. Lionaki S, Blyth ER, Hogan, SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012; 64; 3452–3462.
  8. Grayson PC, Ponte C, Suppiah R, et al. DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis 2022; 81: 309-314.
  9. Robson JC, Grayson PC, Ponte C, et al. DCVAS Investigators. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis 2022; 81: 315-320.
  10. Suppiah R, Robson JC, Grayson PC, et al. DCVAS INVESTIGATORS. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis 2022; 81: 321-326.
  11. Jennette JC, Falk RJ. Pathogenesis of ANCA-associated vasculitis: observations, theories and speculations. Presse Med 2013; 42: 493-498.
  12. de Lind van Wijngaarden RA, van Rijn L, Hagen EC, et al. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known. Clin J Am Soc Nephrol 2008; 3: 237-252.
  13. Watts RA, Scott DG. ANCA vasculitis: to lump or split? Why we should study MPA and GPA separately. Rheumatology (Oxford) 2012; 51:2115–2117.
  14. Mahr A, Specks U, Jayne D. Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum. Rheumatology (Oxford) 2019; 58: 1707-1709.
  1. Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 2024; 83: 30-47.
  2. Yates M, Watts RA, Bajema IM et al. EULAR/ ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016; 75: 1583–1594.
  3. McAdoo SP, Tanna A, Hrušková Z, et al. Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 2017; 92: 693-702.
  4. Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: Early treatment is a must. Autoimmun Rev 2014; 13: 723-729.
  5. Sánchez Álamo B, Moi L, Bajema I, et al. EUVAS. Long-term outcomes and prognostic factors for survival of patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2023; 38: 1655-1665.
  6. Hrušková Z, Tesař V. Pulmorenální syndrom.Vnitr Lek 2020; 66: e20-e25.
  7. Walsh M, Merkel PA, Peh CA, et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med 2020; 382: 622-631.
  8. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232.
  9. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-220.
  10. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371: 1771-1780.
  11. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med 2017; 376: 1921-1932.
  12. Jayne DRW, Merkel PA, Schall TJ, et al. ADVOCATE Study Group. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med 2021; 384: 599-609.
Štítky
Anatomical pathology Forensic medical examiner Toxicology
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#